Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype

  title={Genetic alterations in the 3q26.31-32 locus confer an aggressive prostate cancer phenotype},
  author={Benjamin S. Simpson and Niedzica Camacho and Hayley J. Luxton and Hayley Pye and Ron Finn and Susan Heavey and Jason J. Pitt and Caroline M. Moore and Hayley C. Whitaker},
  journal={Communications Biology},
Large-scale genetic aberrations that underpin prostate cancer development and progression, such as copy-number alterations (CNAs), have been described but the consequences of specific changes in many identified loci is limited. Germline SNPs in the 3q26.31 locus are associated with aggressive prostate cancer, and is the location of NAALADL2 , a gene overexpressed in aggressive disease. The closest gene to NAALADL2 is TBL1XR1 , which is implicated in tumour development and progression. Using… 
2 Citations
The oncological relevance of fragile sites in cancer
It is argued that tumours with predominantly fragile site structural variants represent a distinct mutational signature that warrants further research.


Two Susceptibility Loci Identified for Prostate Cancer Aggressiveness
A multistage, case-only genome-wide association study of prostate cancer cases identifies two loci associated with Gleason score, a pathological measure of disease aggressiveness, and the proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.
Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy
It is suggestive that the loss of the susceptible region on chromosome 10q, which implicates PTEN, FAS and PAPSS2 may serve as genetic predictors of PSA recurrence after radical prostatectomy, and by correlating to patients’ clinico-pathological information, specific prognostic biomarker can be identified.
Genomic hallmarks of localized, non-indolent prostate cancer
It is suggested that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates and numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberration outperformed well-described prognostic biomarkers.